CJC-1295 No DAC / Ipamorelin

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

CJC-1295 No DAC / Ipamorelin Blend — Dual-Axis GH Secretagogue Stack

The CJC-1295 No DAC / Ipamorelin blend combines two mechanistically distinct growth hormone secretagogues into a single research compound targeting the GH axis from complementary receptor systems simultaneously. CJC-1295 No DAC — a modified GHRH analog — acts upstream at the GHRHr on anterior pituitary somatotrophs, priming and amplifying the cellular machinery for GH synthesis and release. Ipamorelin — a selective synthetic pentapeptide — operates through an entirely separate receptor, GHS-R1a (the ghrelin receptor), triggering GH pulse release through a parallel and synergistic pathway. Together, they engage both major regulatory inputs to pituitary somatotrophs in a single administration, producing GH pulse amplitudes that consistently exceed what either peptide achieves alone.

Why the Two-Receptor Approach Matters

GH secretion from the anterior pituitary is regulated by two primary stimulatory inputs — GHRH signaling and ghrelin/GHS-R1a signaling — operating through distinct intracellular cascades that converge on the somatotroph. CJC-1295 No DAC occupies the GHRH axis; Ipamorelin occupies the ghrelin axis. Co-activation of both simultaneously produces a synergistic amplification of GH release that is well-documented in the GHS research literature. Critically, this synergy is achieved while preserving the pulsatile character of GH secretion — a key research variable that distinguishes this stack from exogenous GH administration or long-acting DAC-form protocols.

Ipamorelin’s defining pharmacological characteristic — the feature that has made it the preferred GHRP for combination research — is its exceptional receptor selectivity. Unlike GHRP-2 and GHRP-6, ipamorelin does not stimulate ACTH or cortisol release even at doses more than 200-fold above its GH-effective threshold. This makes it the cleanest available tool for studying isolated GHS-R1a–mediated GH release without confounding HPA axis activation.

Research Applications

The CJC-1295 No DAC / Ipamorelin blend is used in studies examining:

• Dual-axis GH secretagogue synergy and the quantitative amplification of GH pulse amplitude vs. monotherapy controls
• Pulsatile GH release dynamics and somatotroph responsiveness under combined GHRH + GHS-R1a stimulation
• GH/IGF-1 axis dose-response characterization in body composition research models
• Lean mass accrual and adipose tissue reduction under sustained pulsatile GH axis stimulation
• Comparative GH pulse profiling vs. GHRP-2, GHRP-6, and other secretagogue combinations
• Sleep-phase GH secretion timing and circadian axis alignment research
• Metabolic effects of GH/IGF-1 elevation including insulin sensitivity, glucose dynamics, and lipid metabolism
• GHS-R1a biology in gastrointestinal motility models — ipamorelin’s ghrelin receptor activity has been studied in postoperative ileus and gastric emptying research independently of GH endpoints

Specifications

Reconstitution

The blend arrives as co-lyophilized powder and is reconstituted as a single solution with bacteriostatic water prior to use. Use the formula:

Total mg (per peptide) ÷ Volume added (mL) = Concentration per peptide (mg/mL)

Example: 5mg/5mg vial + 2mL BAC water = 2.5mg/mL CJC-1295 No DAC + 2.5mg/mL Ipamorelin

Reconstituted peptide should be stored at 2–8°C and used within 28–30 days.

Protocol Notes

Both peptides in this blend share a short half-life profile (~30 minutes for CJC-1295 No DAC; ~2 hours for Ipamorelin), which makes administration timing relative to endogenous GH rhythm a primary research variable. Pre-sleep administration is the most commonly studied window due to peak somatotroph sensitivity during early slow-wave sleep phases. Fasted states are also frequently studied for their effect on GH pulse amplitude.

Typical research dosing framework:

• Dose range: 100–300mcg per peptide per administration
• Frequency: 1–3 times daily; pre-sleep timing most commonly studied; fasted state preferred in many protocols
• Route: Subcutaneous injection
• Combination rationale: 1:1 ratio is most commonly studied, reflecting equal GHRH and GHS-R1a receptor engagement
• Study duration: 8–16 weeks for body composition and IGF-1 endpoint research

Commonly observed effects in research models:

• Acute / transient: Mild facial flushing, headache, transient water retention, tingling or numbness at extremities — generally short-lived given the brief half-life of both peptides; onset typically within minutes of administration
• Ipamorelin-specific: Minimal off-target hormonal activity — no significant ACTH, cortisol, or prolactin elevation observed even at supraphysiological doses in research models
• Metabolic: IGF-1 elevation warrants monitoring in long-duration protocols; mild shifts in fasting glucose at higher dose ranges
• Other: Injection site irritation; transient hunger or mild appetite stimulation via GHS-R1a engagement

Research Stacks

CJC-1295 No DAC / Ipamorelin is commonly paired in research settings with:

• Sermorelin — Sermorelin is a GHRH analogue with a shorter half-life than CJC-1295; it is studied alongside this blend to examine pulse-pattern and receptor desensitization differences in GH secretagogue research.
• GHRP-2 — GHRP-2 acts on ghrelin receptors (GHSR-1a) with higher GH release potency than Ipamorelin; pairing it with CJC-1295 No DAC in the presence of Ipamorelin allows researchers to compare ghrelin receptor agonist profiles under identical GHRH stimulation conditions.
• Tesamorelin — Tesamorelin is a GHRH analogue studied specifically in visceral adiposity models; it is co-investigated with CJC-1295 No DAC/Ipamorelin to compare GHRH analogue selectivity and GH axis response characteristics.

Purity Guarantee

Every batch is ≥99% purity per peptide. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.